KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Accumulated Depreciation & Amortization (2016 - 2023)

TherapeuticsMD filings provide 14 years of Accumulated Depreciation & Amortization readings, the most recent being $2.5 million for Q3 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 16.46% to $2.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $2.5 million, a 16.46% decrease, with the full-year FY2022 number at $2.4 million, up 24.05% from a year prior.
  • Accumulated Depreciation & Amortization hit $2.5 million in Q3 2023 for TherapeuticsMD, up from $2.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.0 million in Q3 2022 to a low of $686680.0 in Q2 2019.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $2.1 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 98.78% in 2020 and later dropped 16.46% in 2023.
  • TherapeuticsMD's Accumulated Depreciation & Amortization stood at $968824.0 in 2019, then soared by 79.7% to $1.7 million in 2020, then grew by 13.21% to $2.0 million in 2021, then grew by 24.05% to $2.4 million in 2022, then rose by 2.37% to $2.5 million in 2023.
  • The last three reported values for Accumulated Depreciation & Amortization were $2.5 million (Q3 2023), $2.5 million (Q2 2023), and $2.5 million (Q1 2023) per Business Quant data.